Navigation Links
Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Date:1/28/2008

BASKING RIDGE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), reports continued success of their international distribution partnership for the Resurgex(R) line of products in Greece. Since first delivering product to Nutrimedica in April 2006 overall sales in the Greek Market have increased approximately 40% from $30,000 in 2006 to $50,000 in 2007. A successful entry of a U.S. product into the Greek market depends on proper selection of a qualified distributor in Greece, which is knowledgeable of the local market and regulations. The distributor must be capable of developing a proper relationship with the distribution chain of medical institutions, practitioners and proper retail outlets in the medical marketplace. For the past 22 months Millennium has working with Nutrimedica, a well known distributor of nutritional products, in Athens. It has already imported and distributed Resurgex(R) products to hospitals, pharmacies, and direct to patients. Nutrimedica reports that the introduction of Resurgex products has been well received and sales have been steadily increasing. The steady growth has been encouraging due to the fact that no marketing dollars have been allocated to build brand awareness in the marketplace.

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a Surgex(R) sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immunocompromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").


'/>"/>
SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
2. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
3. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
4. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
5. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
6. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
7. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
8. Life Sciences Leader Joins Millennium Board of Directors
9. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
(Date:6/22/2016)... 2016 Research and Markets has announced the ... to their offering. The ... $29.3 billion in 2013. The market is expected to grow at ... to 2020, increasing from $50.6 billion in 2015 to $96.6 billion ... the forecast period (2015 to 2020) are discussed. As well, new ...
(Date:6/22/2016)... ... June 21, 2016 , ... New light-based technologies that facilitate a “look inside” ... to enable both compact, wearable devices for point-of-care diagnostics as well as powerful new ... Recent work and visionary future directions are detailed in a new open-access article by ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):